Artesun

Home / Artesun

Artesun

Home / Artesun

Artesun® 60mg

Parenteral artesunate is recommended by by World Health Organization (WHO) as the preferred choice of treatment for severe malaria caused by Plasmodium falciparum in children and adults.
DRUG NAME

General Name:
Artesunate powder for Injection 60 mg
Main Ingredient:
Artesunic acid which is converted to sodium artesunate on mixing with
sodium bicarbonate.
(3R, 5As,6R,8As,9R,10S,12R,12Ar)-Octahydro-3,6,9 trimethyl 1,3,12-epoxy
12H-pyranol [4,3-j],2benzodioxepim-10-ol, hydrogen succinate.

Structural Formula
Molecular Formula
C19 H28 O8
Molecular Weight

384.43

Product Description

Artesunate for Injection is Artesunate freeze-dried sterile white crystalline powder, which has been separately filled in glass vials under aseptic condition, each vial contains 60mg Artesunate. Artesunate is a single active pharmaceutical ingredient without any other excipients. Adopt 5% Sodium bicarbonate solution as solvent of  rtesunate for Injection when in use. Artesunate for Injection and its solvent are co-packed.

Sodium bicarbonate solution is clear colorless solution filled in 1ml glass ampoule. Inject the 5% sodium bicarbonate solution into the artesunate vial for injection, shake 2-3 minutes and wait until completely dissolved. A clear solution should emerge. When injection, add approximately 5 ml of 5% glucose or physiological saline for injection (0.9% sodium chloride)( For IV injection) or 2 ml of 5% glucose injection or physiological saline (0.9% sodium chloride solution)( For IM injection) to the above solution, a clear solution is also produced.

Pharmacodynamics

The product is a derivative of artemisinin and is a potent and rapidly acting schizontocide active against all causes of malaria in man. Artesunate kills both young and more mature stages of the malaria parasite in red blood cells. The exact mechanism of action of artesunate is not clear.

Pharmacokinetics

After intravenous injection the drug plasma concentrations decline quickly with rapid and complete hydrolysis to dihydroartemisinin, which has a T1/2 of about 45 minutes. The tissue distribution of the product is very wide and the levels in intestine, liver and kidney are relatively high. DHA is eliminated by glucuronidation.

Indication

Used in the treatment of severe malaria.

Administration

The product can be administered intravenously or by intramuscular
injection after dilution with 5% dextrose or physiological saline for
injection (0.9% sodium chloride) to the anterior thigh.

Dose

2.4mg/kg at 0,12 and 24 hours, then daily until oral treatment can be substituted.

Preparation

Inject the 5% sodium bicarbonate solution into the artesunate vial for injection, shake 2-3 minutes and wait until completely dissolved. A clear solution should emerge if a clear solution is not obtained, the preparation should not be used. Insert the syringe needle in the vial to get rid of gas. For IV Injection: add approximately 5 ml of 5% glucose or physiological saline for injection (0.9% sodium chlor ide) to the solution in the vial to create solution containing 10 mg artesunate per ml (total volume is 6 ml). Withdraw the necessary amount of artesunate solution from the vial into a syringe and inject slowly. Speed of IV: 3~4ml/min.

For IM Injection: add approximately 2 ml of 5% glucose injection or physiological saline (0.9% sodium chloride solution) to create a solution containing 20mg of artesunate per ml(total volume is 3ml). Withdraw the necessary amount of artesunate solution from the vial into a syringe and inject.

Dosage form

Parenteral – Powder for injection

Precaution

Inject immediately after reconstitution. Discard if solution is not clear. Do not use in intravenous drip.

Pregnant and Lactating Women

Use only if the benefit outweighs the risk during the first 3 months of pregnancy.

Interactions

Concomitant use with mefloquine may enhance curative effect.

Side Effects

No undesirable effects under recommended dose. In clinical use type1 hypersensitivity reaction have been reported (estimated incidence 1:3000)

Overdosage

Transient reticulocytopenia may occur when an overdose (>3.75mg/kg) is given

Effects on Ability to Drive and Use Machine

There is no information on the effect of artesunate on the ability to drive or use machine

Strength

60mg

Storage

Store in the original container protected from light. Do not store above 30ºC.
Reconstituted and diluted solution should be stored below 30ºC and used within 1 hour.

Keep out of reach of children
Jauhkan ubat-ubat daripada kanak-kanak

Package

Each box contains 1 vial of 7ml Artesunate injection and 1 vial of 5% sodium bicarbonate.

Period of Validity

3 Years

Manufacturer

Name: Guilin Pharmaceutical Co., Ltd.
Manufacturing Address: No. 43 Qilidian Road, Guilin Guangxi, China. Post Code: 541004

Product Registration Holder

RX Pharma Sdn. Bhd. (454934-W)
No. 35, Pusat Pedada, Jalan Pedada, 96000, Sibu, Sarawak, Malaysia.
Tel. +084-333858     084-3116888

Imported and Marketed by

Ubisson Sdn. Bhd. (585048-H)
No. 35, 1st & 3rd Floor, Pusat Pedada, Jalan Pedada,
96000 Sibu, Sarawak, Malaysia.
Tel. +084-333858
REG. No: MAL12050001ACZ

Send us a Message

If you have any inquiry give us a call or leave us a message.